Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTAP101 in Breast or Prostate Cancer with Bone Metastases
NCT02274623Phase 1Completed
- Sponsor
- OPKO Health
- Start
- Dec 2014
- Primary completion
- Feb 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of calcifediol in hypocalcemia and secondary hyperparathyroidism (SHPT), sponsored by OPKO Health. Primary endpoint: Serum calcium at 52 weeks. Started Dec 2014; status: completed.
02
Drugs
calcifediol
03
Conditions
hypocalcemiasecondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02274623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274623.